In response to the occurrence of two fatalities within its VX-880 diabetes drug trial, Vertex Pharmaceuticals has taken the decisive step of suspending the ongoing study.
The company maintains that these incidents are unrelated to the treatment, emphasizing its commitment to transparency and patient safety. In a statement released on Sunday, Vertex expressed regret over the events and pledged to conduct a thorough and comprehensive review. This hiatus aligns with the established protocol, allowing an independent data monitoring committee and global regulators to meticulously scrutinize the trial data.
Despite the setbacks, Vertex highlights that the safety profile of VX-880 is consistent with immunosuppressive drugs, underscoring a persistent positive trend in its development. VX-880, an allogeneic, stem cell-derived therapy designed to stimulate insulin production in islet cells, is currently undergoing a phase 1/2 study. The trial includes individuals with type 1 diabetes, characterized by impaired awareness of hypoglycemia and recurrent hypoglycemic events.
Vertex has successfully enrolled participants for parts A, B, and C of the study, with encouraging outcomes observed in the 14 patients who have received dosages thus far. Notably, all patients in parts A and B, except for one withdrawal, exhibited improved glycemic control and reduced dependence on insulin. The therapy demonstrated islet cell engraftment and the production of endogenous insulin, highlighting its potential in diabetes management.
In a June update, data from six patients indicated that VX-880 was well-received, with no serious side effects recorded. However, this optimistic outlook was temporarily overshadowed when the FDA imposed a clinical hold on the VX-880 program, lasting for two months. Vertex attributed this regulatory intervention to a perceived lack of information to support the escalation of dosage for the product.
The drug initially gained attention in October 2021 when a singular patient reportedly began producing insulin post-treatment. Undeterred by these temporary setbacks, Vertex is actively pursuing newer iterations of the drug, including VX-264. This alternative therapy, administered through a channel array device, aims to bypass the necessity for immunosuppressants.
Simultaneously, Vertex has initiated a phase 1/2 trial for VX-264, with multiple patients having already undergone dosages, according to the latest update on Sunday. The decision to temporarily halt the Phase 1/2 study of VX-880 represents the second instance where Vertex has experienced a pause in the progression of its diabetes drug.
